Dexcom launches Stelo OTC Glucose Biosensor in the US
Dexcom announced Stelo, its OTC “Glucose Biosensor,” is now available for purchase in the US via its website (view website). Recall, in March 2024, FDA cleared Stelo for use without a prescription for T2DM patients 18 years and older who do not use insulin (previous FENIX insight). Additionally, the company is initiating its “Welcome to Stelo: Personalizing Choices, Revolutionizing Glucose Health” webinar series on August 27, 2024 (view website). Below, FENIX has conducted an analysis of the Stelo product, website, and pricing, including thoughts on Dexcom’s Stelo branding strategy and the impending launch of Abbott’s own OTC products (Lingo and Rio).
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.